ESTIMATED
05/13/2024
05/13/2024
(AS OF MARCH 31)
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 5 | -$0.41 | -$0.41 | -$0.41 |
Q2 2024 | 14 | -$0.39 | -$0.28 | -$0.35 |
Q3 2024 | 9 | -$0.36 | -$0.36 | -$0.36 |
Q4 2024 | 6 | -$0.38 | -$0.38 | -$0.38 |
Q1 2025 | 7 | -$0.39 | -$0.39 | -$0.39 |
Q2 2025 | 8 | -$0.39 | -$0.39 | -$0.39 |
Q3 2025 | 7 | -$0.38 | -$0.38 | -$0.38 |
Q4 2025 | 7 | -$0.39 | -$0.39 | -$0.39 |
Allogene Therapeutics, Inc. last posted its earnings results on Monday, May 13th, 2024. The company reported $-0.38 earnings per share for the quarter, missing analysts' consensus estimates of $-0.38 by $0. The company had revenue of 22,000 for the quarter and had revenue of 95,000 for the year. Allogene Therapeutics, Inc. has generated $-2 earnings per share over the last year ($-2.09 diluted earnings per share) and currently has a price-to-earnings ratio of -1.21. Allogene Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 31st, 2024 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue | 05/13/2024 | Q1 2024 | -$0.38 | -$0.38 | 0 | $11,231 | $22,000 | 03/14/2024 | Q4 2023 | -$0.47 | -$0.51 | -0.04 | $22,000 | $21,000 | 11/02/2023 | Q3 2023 | -$0.53 | -$0.37 | 0.16 | $43,000 | 08/02/2023 | Q2 2023 | -$0.59 | -$0.53 | 0.06 | $44,000 | 05/03/2023 | Q1 2023 | -$0.63 | -$0.68 | -0.05 | $8,917 | $52,000 | 02/28/2023 | Q4 2022 | -$0.71 | -$0.65 | 0.06 | $7,167 | $47,000 | 11/02/2022 | Q3 2022 | -$0.62 | -$0.57 | 0.05 | $49,000 | 08/09/2022 | Q2 2022 | -$0.61 | -$0.52 | 0.09 | $86,000 | 05/04/2022 | Q1 2022 | -$0.59 | -$0.56 | 0.03 | $61,000 | 02/23/2022 | Q4 2021 | -$0.61 | -$0.54 | 0.07 | $-7,692 | $51,000 | 11/04/2021 | Q3 2021 | -$0.56 | -$0.57 | -0.01 | $263,857 | $49,000 | 08/04/2021 | Q2 2021 | -$0.55 | -$0.53 | 0.02 | $13.92 M | $44,000 | 05/05/2021 | Q1 2021 | -$0.48 | -$0.25 | 0.23 | $38.35 M | 02/25/2021 | Q4 2020 | -$0.56 | -$0.53 | 0.03 | $2.71 M | $0 | 11/04/2020 | Q3 2020 | -$0.55 | -$0.52 | 0.03 | $0 | 08/05/2020 | Q2 2020 | -$0.55 | -$0.53 | 0.02 | $224,150 | $0 | 05/06/2020 | Q1 2020 | -$0.57 | -$0.50 | 0.07 | $0 | 02/27/2020 | Q4 2019 | -$0.69 | -$0.58 | 0.11 | $0 | 11/05/2019 | Q3 2019 | -$0.54 | -$0.50 | 0.04 | $0 | 08/07/2019 | Q2 2019 | -$0.47 | -$0.41 | 0.06 | $0 |
---|
A. Allogene Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 31st, 2024 based off last year's report dates.
A. The conference call for Allogene Therapeutics, Inc.'s latest earnings report can be listened to online.
A. The conference call transcript for Allogene Therapeutics, Inc.'s latest earnings report can be read online.
A. Allogene Therapeutics, Inc. (NASDAQ:ALLO) has a recorded annual revenue of $95,000.
A. Allogene Therapeutics, Inc. (NASDAQ:ALLO) has a recorded net income of $95,000. Allogene Therapeutics, Inc. has generated $-2.09 earnings per share over the last four quarters.
A. Allogene Therapeutics, Inc. (NASDAQ:ALLO) has a price-to-earnings ratio of -1.21 and price/earnings-to-growth ratio is -0.13.